Amedeo Smart

Free Medical Literature Service

 

Amedeo

Multiple Sclerosis
  Free Subscription

Articles published in
J Neurol Sci
    April 2026
  1. GELISSEN LMY, Wijburg MT, Strijbis EMM, de Jong BA, et al
    No interferon-beta antibodies in natalizumab-treated multiple sclerosis patients with progressive multifocal leukoencephalopathy.
    J Neurol Sci. 2026;486:125947.
    >> Share

  2. ZHU Y, Zihan Ye
    Comment on "a proof-of-concept study on the relationship between lifetime estrogen exposure, menopausal transition, and neurodegeneration in women with multiple sclerosis".
    J Neurol Sci. 2026;486:125951.
    >> Share

  3. SAHIN A, Ismah, Herawati AA, Mubarak MA, et al
    Methodological considerations in evaluating lifetime estrogen exposure and neurodegeneration in multiple sclerosis.
    J Neurol Sci. 2026;486:125963.
    >> Share

    March 2026
  4. BAHARUDDIN B, Febriza A, Handayani L, Akl MM, et al
    Comments on: "Correlation between blood biomarkers and patient-reported outcomes (PROs) of depression and mental health scores in individuals with multiple sclerosis (iwMS)".
    J Neurol Sci. 2026;485:125901.
    >> Share

  5. SCHUMACHER FL, Cutter G, Burd CE, Archer K, et al
    Clocks out of sync: Increased epigenetic aging variability in multiple sclerosis.
    J Neurol Sci. 2026;485:125904.
    >> Share

  6. PETRACCA M, Cocozza S, Cuocolo R
    Response to letter to the editor: Authors response to comment on "Predictors of short-term, relapse-independent progression in multiple sclerosis: A machine learning approach based on clinical data and conventional MRI-derived features".
    J Neurol Sci. 2026 Mar 27:125887. doi: 10.1016/j.jns.2026.125887.
    >> Share

  7. HAQ MMU, Shoaib SM
    Comment on "Correlation between blood biomarkers and patient-reported outcomes (PROs) of depression and mental health scores in Individuals with Multiple Sclerosis (iwMS)".
    J Neurol Sci. 2026;485:125900.
    >> Share

  8. MOKKAPATI A, Thakkar R, Rani A, Puri D, et al
    Comment on "Predictors of short-term, relapse-independent progression in multiple sclerosis: A machine learning approach based on clinical data and conventional MRI-derived features".
    J Neurol Sci. 2026 Mar 25:125888. doi: 10.1016/j.jns.2026.125888.
    >> Share

  9. SUKUMAR M, Annadurai K
    Comment on "Cost-effectiveness analysis of high-efficacy drugs used in the treatment of multiple sclerosis in a large health insurance provider in Brazil".
    J Neurol Sci. 2026;485:125884.
    >> Share

  10. RICAURTE-FAJARDO A, Garcia Gonzalez K, Merino Campo S, Alvarado-De la Hoz C, et al
    Integrated determinants of multiple sclerosis susceptibility: Genetics, environment, infection and the microbiota.
    J Neurol Sci. 2026;484:125865.
    >> Share

  11. YOUNG CA, Rog D, Tanasescu R, Sharrack B, et al
    Fatigue prevalence, interactions with associated symptoms and longitudinal changes in those with multiple sclerosis: Insights from the TONiC study.
    J Neurol Sci. 2026;484:125853.
    >> Share

  12. IANNIELLO A, Piervincenzi C, Pozzilli C, Satriano F, et al
    A proof-of-concept study on the relationship between lifetime Estrogen exposure, menopausal transition, and neurodegeneration in women with multiple sclerosis.
    J Neurol Sci. 2026;484:125854.
    >> Share

    February 2026
  13. IANNIELLO A, Barbuti E, Capobianco MF, Tranfa M, et al
    Predictors of short-term, relapse-independent progression in multiple sclerosis: A machine learning approach based on clinical data and conventional MRI-derived features.
    J Neurol Sci. 2026;483:125846.
    >> Share

  14. UROLAGIN D, Kavyashree MV, Sowmya BA
    Comment on "Plasma neurofilament light chain to evaluate response during cladribine treatment in multiple sclerosis".
    J Neurol Sci. 2026 Feb 18:125820. doi: 10.1016/j.jns.2026.125820.
    >> Share

  15. ALBITES COEN B, Chowdhury P, Messina SA, Keegan BM, et al
    Brain MRI to detect cervical spinal cord critical demyelinating lesions in progressive MS.
    J Neurol Sci. 2026;481:125761.
    >> Share

  16. GUIDO FS, Chen JJ, Decker PA, Fereidan-Esfahani M, et al
    The impact of adding optical coherence tomography in MS diagnostic criteria on the classification of tumefactive demyelination.
    J Neurol Sci. 2026;481:125739.
    >> Share

  17. NICOLELLA V, Terracciano D, Moccia M
    Authors response to Comment on "Plasma neurofilament light chain to evaluate response during cladribine treatment in multiple sclerosis".
    J Neurol Sci. 2026;482:125819.
    >> Share

  18. KARNBROCK L, Herwerth M, Bloemberg GV, Huber M, et al
    Persistent parvovirus B19 DNAemia in B-cell depletion: Implications for family planning in multiple sclerosis and related disorders.
    J Neurol Sci. 2026;482:125796.
    >> Share

  19. BAHARNOORI M, Glanz B, Polgar-Turcsanyi M, Saxena S, et al
    Correlation between blood biomarkers and patient-reported outcomes (PROs) of depression and mental health scores in individuals with multiple sclerosis (iwMS).
    J Neurol Sci. 2026;482:125786.
    >> Share

    January 2026
  20. AERTS S, Geys L, Severijns D, Alkhawajah M, et al
    Directions for advancing prognostic assessments in multiple sclerosis: Qualitative Insights from MS specialist Interviews.
    J Neurol Sci. 2026;481:125756.
    >> Share

    December 2025
  21. JAKIMOVSKI D, Bergsland N, Marr K, Dwyer MG, et al
    Lower vascular cerebral flow and cerebral perfusion may be associated with impairment of the glymphatic system in multiple sclerosis: A cross-sectional DTI-ALPS MRI study.
    J Neurol Sci. 2025;480:125709.
    >> Share

  22. TYAGI B, Toppo L, Biradar A
    Comment on "wearing-off symptoms persist in the majority of patients with multiple sclerosis after switching from natalizumab to ocrelizumab".
    J Neurol Sci. 2025;480:125705.
    >> Share

  23. FUCHS L, Avizov R, Karni A, Golan M, et al
    Siponimod enhances brain-derived neurotrophic factor secretion from immune cells in multiple sclerosis: A longitudinal study.
    J Neurol Sci. 2025;480:125699.
    >> Share

  24. RANGANI F, Nahayati MA, Pahlevan Kakhki M, Aghaee-Bakhtiari SH, et al
    Ocrelizumab modulates the IL-2 signaling pathway and associated lncRNAs in multiple sclerosis.
    J Neurol Sci. 2025;480:125693.
    >> Share

  25. NICOLELLA V, Varelli M, Fasano S, Cantone E, et al
    Plasma neurofilament light chain to evaluate response during cladribine treatment in multiple sclerosis.
    J Neurol Sci. 2025;480:125681.
    >> Share

    November 2025
  26. GELISSEN LMY, Hogenboom L, Toorop AA, Strijbis EMM, et al
    Wearing-off symptoms persist in the majority of patients with multiple sclerosis after switching from natalizumab to ocrelizumab.
    J Neurol Sci. 2025;479:125652.
    >> Share

  27. CWAJNA M, Hamouda AM, Kendall N, Ghozy S, et al
    Factors influencing timeliness of reporting results from multiple sclerosis related clinical trials to ClinicalTrials.gov.
    J Neurol Sci. 2025;479:123744.
    >> Share

    October 2025
  28. PIEDRABUENA MA, Correale J, Silva B, Fiol M, et al
    Efficacy and safety of Cladribine as a therapeutic option in multiple sclerosis patients over 50 years of age: A real-world study.
    J Neurol Sci. 2025;478:123727.
    >> Share

  29. SPIERER R, Hurani M, Stein N, Rawashdeh A, et al
    Trends in prevalence and incidence of multiple sclerosis in the Israeli Jewish and Arab populations.
    J Neurol Sci. 2025;478:123721.
    >> Share

    September 2025
  30. MOODY SN, Manuel M, Willette A, Shirtcliff E, et al
    Corrigendum to "The intersection of race and sex on the clinical and cognitive progression of multiple sclerosis" [Journal of the Neurological Sciences, 466 (2024) 123260].
    J Neurol Sci. 2025;478:123697.
    >> Share

  31. SIPILA J, Jokela M, Solje E
    Municipality-level incidence of clinically diagnosed amyotrophic lateral sclerosis, multiple sclerosis and Parkinson's disease.
    J Neurol Sci. 2025;478:123696.
    >> Share

    August 2025
  32. LADAKIS DC, Ghajarzadeh M, Bhargava P, Absinta M, et al
    Association of paramagnetic rim lesions with patient-reported neuropsychiatric symptoms in multiple sclerosis.
    J Neurol Sci. 2025;477:123657.
    >> Share

    July 2025
  33. ABBADESSA G, Schiavetti I, Bollo L, Cellerino M, et al
    Safety assessment of switching from fingolimod to siponimod: An Italian multicenter prospective study.
    J Neurol Sci. 2025;474:123533.
    >> Share

    June 2025
  34. GLANZ BI, Kletenik I, Singhal T, Zurawski JD, et al
    Subjective cognitive function in individuals with multiple sclerosis: Associations with objective cognitive function, anxiety, depression, and fatigue.
    J Neurol Sci. 2025;475:123593.
    >> Share

  35. KVARTSKHAVA T, Freudenstein D, Sarmiento N, Angstwurm K, et al
    Ocrelizumab as first-line therapy in highly active relapsing-remitting multiple sclerosis.
    J Neurol Sci. 2025;475:123577.
    >> Share

  36. NOVARELLA F, Nicolella V, Fiorenza M, Falco F, et al
    Neurofilament light chain and Alzheimer pathology biomarkers in elderly people with multiple sclerosis.
    J Neurol Sci. 2025;475:123562.
    >> Share

    May 2025
  37. DEVOGELAERE J, Van Remoortel A, Van Laethem D, Faille LD, et al
    Impact of brain volume on coronavirus disease of 2019 severity and subsequent cognitive decline in patients with multiple sclerosis.
    J Neurol Sci. 2025;475:123552.
    >> Share

  38. NYGAARD MKE, Riemenschneider M, Gaemelke T, Dalgas U, et al
    Spatiotemporal alterations of gray matter microstructure in newly diagnosed relapsing-remitting multiple sclerosis patients: A longitudinal diffusion kurtosis MRI study.
    J Neurol Sci. 2025;474:123551.
    >> Share

  39. KELLY H, Sun R, Elkasaby M, Wang A, et al
    Movement disorders in relapsing and progressive MS: A comprehensive prospective evaluation of a large real-life cohort.
    J Neurol Sci. 2025;472:123468.
    >> Share

  40. ZIVLAEI N, Asani DC, Trier NH, Ziogiene D, et al
    Virus-specific antibody responses in multiple sclerosis patients treated with Ocrevus.
    J Neurol Sci. 2025;474:123537.
    >> Share

  41. BERNTSSON SG, Reis J, Zjukovskaja C, Tulek Z, et al
    Climate change impacts the symptomology and healthcare of multiple sclerosis patients through fatigue and heat sensitivity - A systematic review.
    J Neurol Sci. 2025;474:123526.
    >> Share

    March 2025
  42. RISI M, Altieri M, Bisecco A, Rippa V, et al
    Longitudinal assessment of cognitive function in patients with non-relapsing MOG-IgG associated disease.
    J Neurol Sci. 2025;470:123413.
    >> Share

  43. RANGANI F, Rakhshi N, Kadkhoda Mezerji Z, Alikhah A, et al
    Association of IL2RA and multiple sclerosis risk: A case control, systematic review, and meta-analysis study.
    J Neurol Sci. 2025;472:123461.
    >> Share

    February 2025
  44. HELMLINGER B, Seebacher B, Ropele S, Hechenberger S, et al
    Effects of rhythmic-cued gait training on gait-like task related brain activation in people with multiple sclerosis.
    J Neurol Sci. 2025;471:123426.
    >> Share

  45. FILIPPATOU A, Theodorou A, Stefanou MI, Tzanetakos D, et al
    Optical coherence tomography and angiography in multiple sclerosis: A systematic review and meta-analysis.
    J Neurol Sci. 2025;470:123422.
    >> Share

  46. WANG WS, Xia ZY
    Examining the role of optical coherence tomography in multiple sclerosis research and clinical practice.
    J Neurol Sci. 2025;470:123421.
    >> Share

    January 2025
  47. YOUNG CA, Rog D, Sharrack B, Chhetri SK, et al
    Clinical and socio-demographic characteristics of people with multiple sclerosis at the time of diagnosis: Influences on outcome trajectories.
    J Neurol Sci. 2025;470:123409.
    >> Share

  48. MIRMOSAYYEB O, Yazdan Panah M, Moases Ghaffary E, Vaheb S, et al
    The relationship between optical coherence tomography and magnetic resonance imaging measurements in people with multiple sclerosis: A systematic review and meta-analysis.
    J Neurol Sci. 2025;470:123401.
    >> Share

  49. NOCITI V, Romozzi M, Annovazzi P, Fantozzi R, et al
    Effectiveness, safety, and impact on multiple sclerosis course of anti-CGRP monoclonal antibodies.
    J Neurol Sci. 2025;469:123392.
    >> Share

  50. GOPALAKRISHNAN N, Cadden M, Barker L, Healy BC, et al
    Baseline predictors of cross-sectional and longitudinal performance on the symbol digit modalities test in individuals with multiple sclerosis.
    J Neurol Sci. 2025;469:123384.
    >> Share

  51. ENGELS D, Flierl-Hecht A, Shalaginova G, Rek S, et al
    Multiple sclerosis twin study reveals distinct genetic, disease-specific, and psychometric impact on coping with critical life events.
    J Neurol Sci. 2025;469:123381.
    >> Share

    December 2024
  52. D'CUNHA MA, Pandit L, Sudhir A
    MRZ-reaction maybe influenced by immunization status and is not exclusive to multiple sclerosis.
    J Neurol Sci. 2024;468:123365.
    >> Share

  53. MIMORI M, Katsumoto A, Okamoto T, Sato W, et al
    Ofatumumab for multiple sclerosis with disability accumulation.
    J Neurol Sci. 2024;468:123356.
    >> Share

    November 2024
  54. NOMURA T, Muramatsu K, Yaguchi H, Uwatoko H, et al
    Three cases of multiple sclerosis presenting with palmoplantar pustulosis while receiving ofatumumab.
    J Neurol Sci. 2024;467:123315.
    >> Share

  55. KORNILOV SA, Price ND, Gelinas R, Acosta J, et al
    Multi-Omic characterization of the effects of Ocrelizumab in patients with relapsing-remitting multiple sclerosis.
    J Neurol Sci. 2024;467:123303.
    >> Share

    September 2024
  56. MOODY SN, Manuel M, Willette A, Shirtcliff E, et al
    The intersection of race and sex on the clinical and cognitive progression of multiple sclerosis.
    J Neurol Sci. 2024;466:123260.
    >> Share

  57. DOHERTY F, Lynch P, Powell P, Monaghan K, et al
    Feasibility and effectiveness of telerehabilitation on mobility and balance function in multiple sclerosis: A systematic review and meta-analysis.
    J Neurol Sci. 2024;466:123214.
    >> Share

    August 2024
  58. AFZAL SS, Khatri I, Amin SB
    Comment on: Evaluation of the T25FW in minimally disabled people with multiple sclerosis.
    J Neurol Sci. 2024 Aug 22:123189. doi: 10.1016/j.jns.2024.123189.
    >> Share

  59. PATEL AM, Exuzides A, Yermilov I, Dalglish H, et al
    Development and validation of a claims-based algorithm to identify patients with Neuromyelitis Optica Spectrum disorder.
    J Neurol Sci. 2024;463:123110.
    >> Share

  60. CHAPPELL M, Sanderson A, Arun T, Green C, et al
    Literature review and meta-analysis of natalizumab therapy for the treatment of highly active relapsing remitting multiple sclerosis in the 'suboptimal therapy' patient population.
    J Neurol Sci. 2024;464:123172.
    >> Share

  61. GOUIDER R, Souissi A, Mrabet S, Gharbi A, et al
    Environmental factors related to multiple sclerosis progression.
    J Neurol Sci. 2024;464:123161.
    >> Share

    July 2024
  62. WICKS TR, Jakimovski D, Reeves J, Bergsland N, et al
    Comorbid onset of cardiovascular diagnosis and long-term confirmed disability progression in multiple sclerosis: A 15-year follow-up study.
    J Neurol Sci. 2024;464:123156.
    >> Share

  63. TOOROP AA, Wessels MHJ, Gelissen LMY, Hoitsma E, et al
    Influence of personalized extended interval dosing on the natalizumab wearing-off effect - a sub-study of the NEXT-MS trial.
    J Neurol Sci. 2024;462:123102.
    >> Share

  64. PETROVSKA J, Coynel D, Freytag V, de Quervain DJ, et al
    Polygenic susceptibility for multiple sclerosis is associated with working memory in low-performing young adults.
    J Neurol Sci. 2024;463:123138.
    >> Share

  65. NIKITINA V, Santi Laurini G, Montanaro N, Motola D, et al
    Safety of fingolimod in patients with relapsing remitting multiple sclerosis: A descriptive analysis of data from the EudraVigilance database.
    J Neurol Sci. 2024;463:123132.
    >> Share

    June 2024
  66. NICOLELLA V, Fiorenza M, Monteiro I, Novarella F, et al
    Clinical utility of the Lumipulse immunoassay for plasma neurofilament light chain in multiple sclerosis.
    J Neurol Sci. 2024;463:123115.
    >> Share

  67. TRIVEDI RR, Archambault AS, Pavlak C, Gastaldi M, et al
    Prevalence of anti-myelin oligodendrocyte glycoprotein antibodies across neuroinflammatory and neurodegenerative diseases.
    J Neurol Sci. 2024;461:123041.
    >> Share

  68. HILDEBRANDT H, Eling P
    Comments on energy conservation treatments for MS-related fatigue and a new proposal.
    J Neurol Sci. 2024;461:123040.
    >> Share

  69. HELMLINGER B, Pinter D, Hechenberger S, Bachmaier G, et al
    Evaluation of the T25FW in minimally disabled people with multiple sclerosis.
    J Neurol Sci. 2024;462:123073.
    >> Share

    May 2024
  70. FERNANDES L, Coats RO, Mon-Williams M, Hafeez A, et al
    A novel tool for characterising upper limb function in progressive multiple sclerosis through kinematic assessment.
    J Neurol Sci. 2024;462:123068.
    >> Share

  71. MANNI A, Oggiano F, Palazzo C, Panetta V, et al
    Clinical and biological predictors of Cladribine effectiveness in Multiple Sclerosis: A real-world, single Centre study considering a two-year interval from year-2 dosing.
    J Neurol Sci. 2024;462:123070.
    >> Share

  72. LOREFICE L, Piras C, Sechi V, Barracciu MA, et al
    Spinal cord MRI activity in multiple sclerosis: Predictive value for relapses and impact on treatment decisions.
    J Neurol Sci. 2024;462:123057.
    >> Share

  73. PIEDRABUENA MA, Correale J, Fiol M, Marrodan M, et al
    Selection of disease modifying therapies in multiple sclerosis based on patient's age and disease activity: Data from a nationwide registry.
    J Neurol Sci. 2024;461:123052.
    >> Share

  74. JAKIMOVSKI D, Qureshi F, Ramanathan M, Jalaleddini K, et al
    Glial cell injury and atrophied lesion volume as measures of chronic multiple sclerosis inflammation.
    J Neurol Sci. 2024;461:123055.
    >> Share

  75. SKARLIS C, Papadopoulos V, Raftopoulou S, Mavragani CP, et al
    Association of B-cell activating factor gene variants with serum anti-JCV antibody positivity in male patients with multiple sclerosis under natalizumab treatment: Implications for progressive multifocal leukoencephalopathy risk stratification.
    J Neurol Sci. 2024;461:123046.
    >> Share

    March 2024
  76. CHAER LER, de Mendonca JM, Del Negro MC, Titze-de-Almeida R, et al
    Differential diagnosis between multiple sclerosis and leukodystrophies - A scoping review.
    J Neurol Sci. 2024;459:122969.
    >> Share

  77. BERNARDES C, Fernandes C, Cunha C, Nunes C, et al
    Natalizumab extended interval dosing: what about wearing-off effect?
    J Neurol Sci. 2024;458:122930.
    >> Share

    February 2024
  78. RECHTMAN A, Zveik O, Haham N, Freidman-Korn T, et al
    Thyroid hormone dysfunction in MOGAD and other demyelinating diseases.
    J Neurol Sci. 2024;457:122866.
    >> Share

  79. BALCOM EF, Smyth P, Kate M, Vu K, et al
    Disease-modifying therapy use and health resource utilisation associated with multiple sclerosis over time: A retrospective cohort study from Alberta, Canada.
    J Neurol Sci. 2024;458:122913.
    >> Share

  80. KUSNIRIKOVA ZK, Kacirova I, Pesakova V, Hradilek P, et al
    Serum teriflunomide concentrations in routine multiple sclerosis therapy: A cross-sectional pilot study.
    J Neurol Sci. 2024;458:122910.
    >> Share

    January 2024
  81. ZANETTA C, Faustino P, Guerrieri S, Nozzolillo A, et al
    Fast but not furious: Rapid ocrelizumab infusion as a strategy to optimize multiple sclerosis patients' management.
    J Neurol Sci. 2024;457:122897.
    >> Share

  82. MOTEGI H, Kufukihara K, Kitagawa S, Sekiguchi K, et al
    Non-lesional white matter changes depicted by q-space diffusional MRI correlate with clinical disabilities in multiple sclerosis.
    J Neurol Sci. 2024;456:122851.
    >> Share

  83. HJAERESEN S, Benedikz E, Sejbaek T, Axelsson M, et al
    High temperature requirement A1 and macrophage migration inhibitory factor in the cerebrospinal fluid; a potential marker of conversion from relapsing-remitting to secondary progressive multiple sclerosis.
    J Neurol Sci. 2024;457:122888.
    >> Share

  84. RAGHIB MF, Bao F, Elkhooly M, Bernitsas E, et al
    Choroid plexus volume as a marker of retinal atrophy in relapsing remitting multiple sclerosis.
    J Neurol Sci. 2024;457:122884.
    >> Share

    December 2023
  85. KREITER D, Postma AA, Hupperts R, Gerlach O, et al
    Hallmarks of spinal cord pathology in multiple sclerosis.
    J Neurol Sci. 2023;456:122846.
    >> Share

  86. MARANTOS T, Kyriazopoulou E, Lekakis V, Voumvourakis KI, et al
    Immunogenicity and safety of vaccines in multiple sclerosis: A systematic review and meta-analysis.
    J Neurol Sci. 2023;456:122852.
    >> Share

  87. DOHERTY F, Powell P, McBride C, Monaghan K, et al
    Physical Telerehabilitation interventions for Gait and balance in Multiple sclerosis: A Scoping review.
    J Neurol Sci. 2023;456:122827.
    >> Share

    November 2023
  88. KHORMI I, Al-Iedani O, Alshehri A, Ramadan S, et al
    MR myelin imaging in multiple sclerosis: A scoping review.
    J Neurol Sci. 2023;455:122807.
    >> Share

  89. JAKIMOVSKI D, Kavak KS, Zakalik K, McGraw C, et al
    Patient-reported outcomes based on discontinuation or continuous treatment with natalizumab: New York State Multiple Sclerosis Consortium (NYSMSC) study.
    J Neurol Sci. 2023;455:122781.
    >> Share

  90. DITTEL LJ, Dittel BN, Brod SA
    Ingested (oral) adrenocorticotropic hormone (ACTH) inhibits interleukin-17 in the central nervous system after adoptive transfer of T helper (Th)1/Th17 T cells in the mouse model of multiple sclerosis, experimental autoimmune encephalomyelitis.
    J Neurol Sci. 2023;456:122779.
    >> Share

    October 2023
  91. MIRMOSAYYEB O, Yazdan Panah M, Mokary Y, Ghaffary EM, et al
    Optical coherence tomography (OCT) measurements and disability in multiple sclerosis (MS): A systematic review and meta-analysis.
    J Neurol Sci. 2023;454:120847.
    >> Share

  92. HECHENBERGER S, Helmlinger B, Penner IK, Pirpamer L, et al
    Psychological factors and brain magnetic resonance imaging metrics associated with fatigue in persons with multiple sclerosis.
    J Neurol Sci. 2023;454:120833.
    >> Share

    September 2023
  93. DE LURY AD, Bisulca JA, Lee JS, Altaf MD, et al
    Magnetic resonance imaging detection of deep gray matter iron deposition in multiple sclerosis: A systematic review.
    J Neurol Sci. 2023;453:120816.
    >> Share

  94. MUSTAFA R, Flanagan EP, Duffy DJ, Weinshenker BG, et al
    Laboratory evaluation for the differential diagnosis of possible multiple sclerosis in the United States: A physician survey.
    J Neurol Sci. 2023;453:120781.
    >> Share

    August 2023
  95. OSEN A, Stefoski D, Shoemaker T, Kaplan T, et al
    Cyclophosphamide for severe acute forms of central nervous system inflammatory disorders.
    J Neurol Sci. 2023;451:120693.
    >> Share

    July 2023
  96. PATIL SA, Joseph B, Tagliani P, Sastre-Garriga J, et al
    Corrigendum to "Longitudinal stability of inter-eye differences in optical coherence tomography measures for identifying unilateral optic nerve lesions in multiple sclerosis" [Journal of the Neurological Sciences 449C (2023) Start page-End page/JOTNS
    J Neurol Sci. 2023 Jul 17:120695. doi: 10.1016/j.jns.2023.120695.
    >> Share

  97. JEANTIN L, Boudot de la Motte M, Deschamps R, Gueguen A, et al
    Natalizumab extended-interval dosing in a real-life setting.
    J Neurol Sci. 2023;450:120689.
    >> Share

  98. WEBB LM, Cacciaguerra L, Krecke KN, Chen JJ, et al
    Marked central canal T2-hyperintensity in MOGAD myelitis and comparison to NMOSD and MS.
    J Neurol Sci. 2023;450:120687.
    >> Share

    May 2023
  99. PATIL SA, Joseph B, Tagliani P, Sastre-Garriga J, et al
    Longitudinal stability of inter-eye differences in optical coherence tomography measures for identifying unilateral optic nerve lesions in multiple sclerosis.
    J Neurol Sci. 2023;449:120669.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016